ASCO
Pivotal avelumab data in Merkel cell carcinoma presented at ASCO
June 6, 2016Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma
New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …
AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial
June 6, 2016Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab
Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …
Bristol-Myers Squibb presents Opdivo data at ASCO
June 6, 2016Research and Development, Sales and Marketing ASCO, Bristol-Myers Squibb, opdivo
Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications …
Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS
June 6, 2016Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. The company …
ASCO 2015 roundup: immuno-oncology hits its stride
June 8, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, BMS, CLL, pdl1
One year can make all the difference. The 2014 American Society of Clinical Oncology (ASCO) meeting took place just weeks …
AstraZeneca lung drug shines on
June 1, 2015Sales and Marketing ASCO, AZD9291, AstraZeneca, MEDI4736, NSCLC, Tafinlar
AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …
BMS immunotherapy combination impresses at ASCO
June 1, 2015Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo
Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …
Pfizer breast cancer drug delivers
June 1, 2015Sales and Marketing ASCO, AZ, Faslodex, Pfizer, breast cancer, brett wells
A Phase III study on Pfizer’s treatment Ibrance in combination with hormone therapy has revealed the drug more than doubled …
BMS’ Opdivo improves lung cancer survival
May 29, 2015Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo
A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …
Novartis reveals ASCO plans
May 27, 2015Sales and Marketing ASCO, GSK, Novartis
Novartis’ first ASCO conference since buying GlaxoSmithKline’s oncology business will be showcasing drugs from the acquisition. The two firms swapped …
Industry awaits key immunotherapy results at ASCO
May 20, 2015Research and Development, Sales and Marketing ASCO, Cancer, oncology, pharma
This year’s American Society of Clinical Oncology (ASCO) conference has a strong focus on immunotherapy, as pharma ramps up its …
Merck KGaA reveals ASCO plans
May 15, 2015Sales and Marketing ASCO, Merck, Merck KGaA, Merck Serono, avelumab
Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, and like other firms it …
AstraZeneca eyes success in immuno-oncology combinations
May 14, 2015Sales and Marketing ASCO, AZ, AstraZeneca, CTLA-4, MEDI4736
An investigational immuno-oncology drug combination from AstraZeneca has shown promise in its most recent trial, although concerns over its side …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
